# Piper Sandler Resumes Supernus Coverage With Overweight Rating

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/49234
Published: 2026-11-05T11:29:30.000Z
Updated: 2026-11-05T11:29:30.000Z
Section: Investing

> The firm set a $47 price target and linked its view to the merger with Indivior announced in August.

Piper Sandler resumed coverage of Supernus Pharmaceuticals (SUPN) on Wednesday, Nov. 4, with an Overweight rating and a $47 price target, tying its view to the company’s announced merger with Indivior.

The firm said combining the businesses would expand the merged company’s capacity for business development and acquisitions compared with what Supernus and Indivior could pursue separately.